TLX:NASDAQTelix Pharmaceuticals Limited Analysis

Telix trades at $9.94, currently sitting just above its 20‑day SMA (9.53) but still under the 50‑day SMA (10.17), with a bullish MACD histogram (+0.07) and a neutral RSI (54.5). Volume is on the rise, yet the stock remains volatile (≈48% 30‑day) and tracks a beta near 1, indicating market‑wide sensitivity. The price is perched between a support of $8.69 and resistance near $10.28, while sentiment is extreme greed (FGI 90.48).
Fundamentally, TLX posted a 49% revenue surge to $804 M and maintains a solid 47% gross margin, but operating margins are thin (1.9%) and earnings are still negative (trailing EPS –$0.02). The balance sheet is leveraged, with $467 M debt versus $142 M cash, and no dividend is paid. Forward EPS is projected at $0.236, implying a forward P/E of 42, yet analysts price the stock at a mean target of $20.7, suggesting over 100% upside. Recent MoUs with United Imaging and collaborations on PSMA‑PET imaging reinforce the pipeline’s commercial potential.